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Recovery from pneumonia
requires efferocytosis which
is impaired in smokers and
those with low body mass
index and enhanced by statins
Background Efferocytosis (the phagocytosis
of apoptotic self cells) is a key mechanism in
the resolution of inﬂammatory processes such
as community-acquired pneumonia (CAP).
Efferocytosis therefore represents a modiﬁable
target for therapy aimed at enhancing intrinsic
recovery mechanisms. It is currently not known
which patients recovering from CAP would
mostly beneﬁt from a strategy aimed at
enhancing efferocytosis.
Methods We recruited a cohort of patients
with CAP admitted to a hospital in Liverpool.
One month into recovery, subjects were invited
for research bronchoscopy and bronchoalveolar
lavage. An ex vivo efferocytosis assay was
performed by challenging alveolar
macrophages with autologous, apoptotic
neutrophils. The percentage of alveolar
macrophages that had undergone efferocytosis
was determined by ﬂow cytometry. We
conducted a multivariable regression using a
linear mixed effects model to determine which
clinical parameters were most closely
associated with efferocytosis.
Results We observed high rates of
comorbidity among this CAP cohort.
Efferocytosis was measured in 22 subjects. We
assessed multiple combinations of clinical
parameters for association with efferocytosis
and found the best-ﬁtting model included an
interaction between smoking status and prior
statin use—smoking being associated with
decreased efferocytosis and statin use with
increased efferocytosis. These effects were
modiﬁed by an association between
efferocytosis and body mass index (BMI), such
that as BMI increased so did efferocytosis.
Conclusions This is the ﬁrst study to
measure efferocytosis in patients recovering
from CAP. The results suggest that smokers
with low BMI have impaired efferocytosis and
may beneﬁt from a statin to boost recovery.
INTRODUCTION
Among the 80% of patients who survive
an admission with community-acquired
pneumonia (CAP), a proportion suffers
prolonged symptoms.1 During recovery
from pneumonia, dead and dying neutro-
phils must be cleared. This phagocytosis
of apoptotic ‘self ’ cells, called efferocyto-
sis, is defective in idiopathic pulmonary
ﬁbrosis and COPD.2 The efferocytosis of
apoptotic neutrophils has been studied in
pneumonic mice but not in humans reco-
vering from CAP.3 In patients with CAP,
clinical severity markers are associated
with short-term mortality risk, but the
association of these factors with efferocy-
tosis following CAP is not known. If
pre-CAP clinical factors were associated
with efferocytosis, then pro-resolution
therapy to reduce post-CAP adverse
events would become a possibility. We
conducted a prospective cohort study of
adults hospitalised for CAP. We hypothe-
sised that ex vivo efferocytosis of autolo-
gous apoptotic neutrophils by alveolar
macrophages would vary in association
with patient characteristics.
METHODS
Subjects recruited from two UK Hospitals
between February 2011 and March 2013
had CAP (British Thoracic Society deﬁn-
ition), were aged >16 years and were
recruited within 24 hours of their ﬁrst
dose of in-hospital antibiotic. We
excluded patients requiring invasive venti-
lation, requiring renal replacement
therapy, with cystic ﬁbrosis (CF), non-CF
bronchiectasis, lung cancer, lung metasta-
ses, advanced cancer of any type, immu-
nocompromise (including systemic
corticosteroids), those treated palliatively
or admitted within 14 days. At 1 month,
subjects were invited for bronchoscopy
with bronchoalveolar lavage (BAL) and
were excluded if they were at increased
risk of complications. BAL was performed
as previously published with 200 ml saline
instilled into the right middle lobe (RML)
bronchus.4 BAL was ﬁltered, pelleted,
washed and resuspended in Iscove’s
Modiﬁed Dubecco’s Medium (IMDM)
with human AB serum and antibiotics.
Cells were seeded into 48 well plates and
incubated for 4 hours before the medium
was replaced with antibiotic-free IMDM.
Ex vivo autologous apoptotic neutro-
phils were derived by published protocol.5
Prior to incubation, the neutrophils were
divided into two aliquots: one stained
green and the other unstained. The effero-
cytosis assay was a modiﬁcation of pub-
lished protocols.6 After overnight
incubation, the media was removed from
the macrophages and unstained neutro-
phils, stained neutrophils or medium
added to each well (see online
supplementary ﬁgure S1). After 90 min
co-culture, the medium was removed and
the macrophages washed to remove unin-
gested neutrophils. Macrophages were
detached with cold phosphate-buffered
saline (PBS), washed, quenched and then
acquired on the cytometer.
The ﬂow cytometric gating strategy (see
online supplementary ﬁgure S2) involved
the separation of uningested neutrophils
from macrophages by light scatter as pre-
viously published.6 Using R, associations
with efferocytosis were analysed by mul-
tiple regression. The mean of efferocytosis
experimental replicates was used for uni-
variate analysis; then, a maximal linear
mixed effects model was constructed
using efferocytosis as the response vari-
able, correlated (p>0.05) variables from
the univariate analysis as ﬁxed effects and
‘subject id’ as a random effect. The
random effect enabled us to separate the
stochastic variation associated with experi-
mental technique from between subject
variations. Backwards elimination derived
the minimum set of explanatory variables
required to give a statistically acceptable
ﬁt.
RESULTS
Of 169 subjects recruited, efferocytosis was
analysed in 22 (ﬁgure 1 and online
supplementary tables S1 and S2). Univariate
analysis (see online supplementary table S3)
revealed a trend towards higher efferocyto-
sis values with improved symptomatic
recovery (see online supplementary ﬁgure
S3), but no relationship with age. Smoking
status, prior statin use, body mass index
(BMI) and gender correlated with efferocy-
tosis. Those variables were combined in a
linear mixed effects model which left three
variables with statistically signiﬁcant effects:
smoking status, prior statin use and BMI. As
BMI increased, so did efferocytosis.
Smoking was associated with lower rates of
efferocytosis. Subjects who were taking
statins had higher rates of efferocytosis.
Analysis for interactions showed the model
with the best data-ﬁt included an interaction
between smoking status and prior statin use,
with adjustment for BMI (ﬁgure 2). The
interaction was such that the
statin-associated increase in efferocytosis
was largest in those who were active
smokers. The ﬁnal model explained 42.6%
of variation in the data, of which 90.1%
was the difference between patients and
9.9% was within experimental replicates.
DISCUSSION
This is the ﬁrst study of efferocytosis
during recovery from CAP. After adjust-
ment for BMI, the strongest associations
with efferocytosis were smoking status
and statin use prior to CAP.
Strengths of this study include the use
of autologous neutrophils as a patho-
physiologically appropriate apoptotic
target for the efferocytosis assay, the use
of linear mixed effects modelling to
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quantify the contributions of experimen-
tal and between-patient variations and the
ﬂow cytometric method used. Limitations
include the small study size, lower median
age and lower range of severity than that
in clinical practice. It is not known if CAP
in humans has an effect on efferocytosis
or whether any such effect would be local
or generalised, but we consistently
lavaged the RML, and three of the
patients were recovering from RML CAP.
It is possible that recent local inﬂamma-
tion by the RML CAP may have affected
rates of local efferocytosis; however, in
our univariate analysis, there was no
Figure 1 Bronchoscopy ﬂow chart. Approximately half of the subjects assessed were deemed ineligible for research bronchoscopy—the majority of
those being excluded on safety grounds due to comorbidity. CAP, community-acquired pneumonia
Figure 2 Interactions between covariates in the linear mixed effects model. The result of the linear regression was a model that included the
interaction of smoking and statin with adjustment for body mass index (BMI). The efferocytosis values ﬁtted by the model (including all replicates)
are on the Y-axis, with BMI on the X-axis. Points are ‘jittered’ to avoid overlap. The modelled interactions of each level of smoking and statin are
represented by six straight lines. These lines are displayed in colour pairs based on smoking status. The y-intercepts of each line are derived from the
model, as is the BMI-dependent slope of 0.6. From these lines, it can be seen that without statins the differences between smoking status are large,
but with statins the differences are smaller. The magnitude of the statin effect appears greatest in smokers. There was no association between
efferocytosis and sampling from the right middle lobe (RML).
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statistically signiﬁcant difference in effero-
cytosis associated with RML involvement.
Previous studies have found that cigar-
ette smoke affects molecular pathways
that lead to the activation and membrane
localisation of the enzyme Rac which
facilitates the cytoskeletal rearrangements
needed for efferocytosis.7 Statins cause
the enzymes Rac and RhoA to sequester
in the cytosol, resulting in increased effer-
ocytosis of apoptotic neutrophils.8 These
studies suggest smoking and statins have
antagonistic effects on Rac1 and RhoA,
and as a consequence opposite effects on
efferocytosis, providing a possible mech-
anistic explanation for our ﬁnding of a
negative association between efferocytosis
and smoking, a positive association with
statins and a statistical interaction between
smoking and statin use.
We also showed a novel association
between BMI and efferocytosis. Previous
studies have shown that reduced CAP
mortality is associated with high BMI9
and that low BMI is associated with
increased risk of developing CAP.10
Differential rates of efferocytosis may
explain these correlations.
Our study suggests that smokers with
CAP and low BMI may beneﬁt most from
augmented efferocytosis; a statin would
be an appropriate candidate for such a
trial.
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